MobileODT, a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million, the company announced Wednesday.
Follow Israel Hayom on Facebook and Twitter
This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI's goal of reducing suffering and death due to cancer.
According to the WHO, cervical cancer is the fourth-most prevalent cancer in women. In 2018, over half a million women worldwide were diagnosed with cervical cancer and some 311,000 died of it.
The grant was awarded to MobileODT to perform a large-scale clinical trial validating the efficacy of the company's EVA VisualCheck (TM) artificial intelligence technology as a cervical screening Clinical Decision Support Tool at the Point of Care and providing results in under 60 seconds. The VisualCheck AI technology will be compared to standard of care methods such as Pap smear, and visual inspection of the cervix.
"AI has a lot of potential to revolutionize care for women worldwide. We are excited to test the technology and validate its accuracy and clinical feasibility," said Dr. Miriam Cremer, Associate Professor of Obstetrics and Gynecology from Cleveland Clinic, one of the key researchers in the trial, which is scheduled to begin in the third quarter of 2021 on a population of 10,000 subjects.
